GRPR and neoplasm: GRPR targeting potential of 68Ga- and 177Lu-labelled ProBOMB2—a novel BBN derivate—was investigated in preclinical models of GRPR-positive PC-3 human prostate cancer tumor-bearing male immunocompromised mice [17].